Chimeric antigen receptor T-cell therapy, or CAR T, has made a big impact on the treatment of certain blood cancers, allowing patients with relapsed/refractory disease to live longer, healthier lives. But in clinical study, ...
May 5, 2022
0
51
Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer. Compared to traditional drugs, engineered immune cells are more precise and sophisticated in their ability ...
Apr 15, 2022
0
27
Ovarian cancer is a difficult to diagnose malignancy that is often caught at a more advanced stage. Treatments for this cancer have changed little over the past few decades, with surgery and chemotherapy being the most common ...
Apr 14, 2022
0
62
Researchers at University of California San Diego School of Medicine and Moores Cancer Center at UC San Diego Health, with collaborators at La Jolla Institute for Immunology and elsewhere, have further elucidated how ovarian ...
Apr 11, 2022
0
41
Immunotherapies for cancer rely on recruiting the patient's immune system, but they still fall far short of tapping into the entire arsenal of the body's natural defenses. In fact, most such therapies draw on one type of ...
Mar 23, 2022
0
77
Pancreatic cancer is notoriously difficult to cure or even treat. Now, a new strategy devised by scientists at Albert Einstein College of Medicine has succeeded in making pancreatic tumors visible to the immune systems of ...
Mar 23, 2022
0
138
The prognosis for ovarian cancer patients is grim: Less than half of high-grade serous ovarian cancer (HGSC) patients survive past five years from diagnosis. Initially, the tumors typically respond well to chemotherapy, but ...
Feb 23, 2022
0
18
Researchers at Texas A&M University are pushing organ-on-a-chip devices to new levels that could change the way clinicians approach cancer treatment, particularly ovarian cancer. A team has recently submitted a patent disclosure ...
Jul 23, 2021
0
800
The prognosis of ovarian cancer is poor, with an estimated five-year survival of only 40% for advanced disease, the stage at which most ovarian carcinomas are diagnosed. These poor outcomes are partly due to the lack of effective ...
Feb 3, 2021
0
42
Any given tumor is composed of a multitude of cell types that can each look or behave differently from its neighbors. An emerging body of research suggests that these differences can influence disease progression or the way ...
Nov 18, 2020
0
69
